World Allergy Organization Journal最新文献

{"title":"Clinical outcomes of allergen immunotherapy in children in Latin America: Treatment with polymerized allergen extracts of <i>Dermatophagoides pteronyssinus</i> and <i>Dermatophagoides farinae</i>.","authors":"Ricardo Cardona-Villa, Sandra Del Pozo, Susana Uribe-García, Víctor Daniel Calvo-Betancur, Enrique Fernández-Caldas, Jorge Sánchez","doi":"10.1016/j.waojou.2025.101094","DOIUrl":"10.1016/j.waojou.2025.101094","url":null,"abstract":"<p><strong>Background: </strong>Subcutaneous allergen immunotherapy (SCIT) is recognized as an effective and safe treatment for children and adults suffering from allergic respiratory diseases driven by house dust mites (HDM) in tropical regions.</p><p><strong>Objectives: </strong>To assess the clinical effectiveness and safety of SCIT using glutaraldehyde-polymerized allergen extracts of <i>Dermatophagoides pteronyssinus</i> and <i>D. farinae</i> in Colombian pediatric patients.</p><p><strong>Methods: </strong>A retrospective, observational study including 49 children diagnosed with HDM-induced allergic rhinitis, with or without asthma, who were treated with SCIT for 1 year. Primary endpoints were measured using the Combined Symptom and Medication Score (CSMS). Secondary outcomes were asthma medication use and Asthma Control Test (ACT) scores.</p><p><strong>Results: </strong>Significant improvement in CSMS (median reduction: -0.8; p = 0.015) and ACT scores (median increase: -1.3; p = 0.015) were observed within 3 months; 76% of patients had at least a 20% of reduction of the CSMS compared to baseline after 6 months with immunotherapy (IT). Medication use for asthma decreased significantly after 1 year (p = 0.035).</p><p><strong>Conclusion: </strong>SCIT using polymerized HDM extracts demonstrated to be effective and safe in allergic pediatric populations.</p>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"101094"},"PeriodicalIF":4.3,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab.","authors":"Koremasa Hayama, Mana Ito-Watanabe, Hideki Fujita","doi":"10.1016/j.waojou.2025.101098","DOIUrl":"10.1016/j.waojou.2025.101098","url":null,"abstract":"<p><p>Dupilumab is effective for chronic spontaneous urticaria (CSU), but its clinical benefit of switching to dupilumab in omalizumab-resistant CSU remains unclear. This prospective pilot study evaluated the effectiveness of dupilumab in 12 CSU patients whose Urticaria Control Test (UCT) scores remained <12 after receiving at least 4 doses of omalizumab. Patients were transitioned to dupilumab after inadequate response to omalizumab. UCT scores were assessed at baseline, and 1 and 4 months after starting dupilumab. Laboratory parameters including eosinophil and basophil counts, total IgE, C-reactive protein, and anti-thyroid peroxidase antibody levels were also evaluated. The mean UCT score at the initiation of dupilumab was 6.5 ± 2.2, improving to 8.4 ± 3.0 at 1 month (P = 0.016) and 8.1 ± 3.9 at 4 months (P = 0.045), compared to 4.9 ± 3.1 before omalizumab treatment. Three patients achieved UCT ≥12 after switching to dupilumab. No significant differences were found in clinical characteristics or laboratory markers between effective and ineffective groups. Interestingly, 3 patients who returned to omalizumab after inadequate response to dupilumab achieved UCT ≥12. Dupilumab may improve disease control in a subset of omalizumab-resistant CSU patients. Further studies are needed to identify which patients benefit most from switching therapies.</p>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"101098"},"PeriodicalIF":4.3,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-immunoglobulin E-mediated gastrointestinal food allergies in children with Down syndrome: An epidemiological study.","authors":"Fumiko Okazaki, Hiroyuki Wakiguchi, Yuno Korenaga, Mototsugu Shimokawa, Tsuyoshi Tanabe, Ken Fukuda, Masanari Hasegawa, Miho Shimizu, Reiji Hirano, Tadashi Moriwake, Mai Kawamura, Hiroshi Tateishi, Ryo Kadoya, Yasumasa Tsuda, Takaomi Sekino, Norimichi Tashiro, Hirofumi Inoue, Yoshiko Nawata, Makoto Mizutani, Takashi Maki, Kenji Nakatsuka, Shunji Hasegawa","doi":"10.1016/j.waojou.2025.101103","DOIUrl":"10.1016/j.waojou.2025.101103","url":null,"abstract":"<p><strong>Background: </strong>Non-immunoglobulin E-mediated gastrointestinal food allergies (non-IgE-GI-FAs) in children with Down syndrome (DS) tend to be more severe, with some children presenting with sepsis-like symptoms. However, the epidemiology of this condition remains unknown. This study aimed to investigate the prevalence rate and clinical characteristics of non-IgE-GI-FAs in children with DS.</p><p><strong>Methods: </strong>This study included 115 children with non-IgE-GI-FAs diagnosed at 13 hospitals in Yamaguchi Prefecture, Japan, between January 1, 2011, and December 31, 2020. The children were classified into DS and non-DS groups, and their clinical characteristics were retrospectively compared.</p><p><strong>Results: </strong>Among the 115 children with non-IgE-GI-FAs, 7 and 108 were included in the DS and non-DS groups, respectively. During the study period, 184 children with DS were born in Yamaguchi prefecture, and 7 developed non-IgE-GI-FAs. In this study, the prevalence rate of non-IgE-GI-FAs was 3.8% (7/184) in children with DS and 0.11% (108/98,989) in children without DS. No significant differences were observed in causative foods, age at onset, age at diagnosis, or age at confirmed clinical remission between the 2 groups. Most children in both groups experienced vomiting and diarrhea, but none had hypothermia. Sepsis-like symptoms, such as lethargy (71.4% vs. 24.1%, <i>P</i> = 0.0150), hypotension (42.9% vs. 0.9%, <i>P</i> = 0.0006), and fever (57.1% and 8.3%, <i>P</i> = 0.0030), were significantly more common in the DS group than in the non-DS group.</p><p><strong>Conclusions: </strong>The prevalence rate of non-IgE-GI-FAs was 3.8% in children with DS and 0.11% in children without DS. Non-IgE-GI-FAs in children with DS were significantly more severe than those in children without DS. Non-IgE-GI-FAs should be considered a differential diagnosis when sepsis-like symptoms are observed in children with DS.</p>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"101103"},"PeriodicalIF":4.3,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel recognition of the major allergen, Hum j 1, from <i>Humulus japonicus</i> pollen.","authors":"Qiong Li, Yue Zhu, Fu-Xian Zhang, Ya-Li Cheng, Yong-Shi Yang, Ji-Fu Wei, Jin-Lyu Sun, Zhi-Qiang Xu","doi":"10.1016/j.waojou.2025.101104","DOIUrl":"10.1016/j.waojou.2025.101104","url":null,"abstract":"<p><strong>Background: </strong><i>Humulus japonicus</i> (HJ) is widely spread in East Asia. HJ pollen is one of the common allergens in the north of China in autumn. However, some controversy exists regarding the major allergen Hum j 1 from HJ pollen, which hamper its application in the diagnosis and treatment of HJ pollen allergy. Further studies are urgently needed to improve this aspect.</p><p><strong>Methods: </strong>During our work in isolating potential allergens from HJ pollen, we found a protein of around 10 kDa with obvious immunoglobulin E (IgE) binding activity than other fractions. This protein was then further identified by mass spectrometry, and its gene sequence was matched from our in-house built transcripts of HJ pollen based on the identified peptides. The gene was further confirmed by polymerase chain reaction (PCR) cloning, and the recombinant protein was prepared by <i>Escherichia coli</i> (<i>E. coli</i>) expression system. The circular dichroism (CD) spectrum of natural and recombinant proteins was analyzed. The allergenicity of its natural and recombinant forms was assessed in Chinese patients and the relationship between the epitopes and its structural features was investigated under reduced, denatured and heat-treated conditions.</p><p><strong>Results: </strong>The 10 kDa protein with obvious IgE binding activity was finally purified from HJ pollen with a purity of 98%. The liquid chromatography-tandem mass spectrometry (LC-MS/MS) results identified 6 internal peptides, which covered 98.9% of the mature sequence of the 10 kDa protein with the N-terminal segment as DNCFENGMK. We surprisingly found that the 10 kDa protein was previously underrecognized Hum j 1 based on its limited sequence of only N-terminus. The sequence failed to be classified into any protein families by InterPro functional analysis, indicating the Hum j 1 could be the orphan protein. Both natural and recombinant Hum j 1 exhibited similar CD spectrum. The specific IgE binding rate against them was determined as 79% (11/14) in patients' serum with HJ pollen allergy by ELISA with a strong correlation in absorbance values (R² = 0.99, <i>p</i> < 0.0001) and decreased by 76%-87% after broking disulfide bonds, with no significant change after heat treatment or urea treatment.</p><p><strong>Conclusion: </strong>These findings first provided solid evidence about the major allergen Hum j 1 in HJ pollen and resolved its unclear status. The defined sequence could enhance understanding of Hum j 1 properties and aid in producing high-quality recombinant allergens for diagnosing and treating HJ pollen allergy.</p>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"101104"},"PeriodicalIF":4.3,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atopic dermatitis occurrence and progression and allergen immunotherapy: A real-world, retrospective cohort study in Germany","authors":"Oliver Pfaar MD ,&nbsp;Hartmut Richter ,&nbsp;Thomas Müller PhD ,&nbsp;Jasmin Weber PhD ,&nbsp;Angelika Sager MD ,&nbsp;Katja Nemat MD","doi":"10.1016/j.waojou.2025.101090","DOIUrl":"10.1016/j.waojou.2025.101090","url":null,"abstract":"<div><h3>Background</h3><div>Allergen immunotherapy (AIT) represents the sole causal and preventive disease-modifying therapy currently available for allergic diseases. However, it must be acknowledged that controlled studies feature inherent results bias due to specific criteria and monitoring during the study. This real-world evidence (RWE) study was therefore designed to analyse data on large longitudinal prescriptions of different types of AIT in order to evaluate the therapeutic effect on the progression and onset of atopic dermatitis (AD).</div></div><div><h3>Methods</h3><div>The analysis was based on IQVIA™ LRx prescription data for statutorily insured patients in Germany. A total of 122,600 patients were included in the study, and we identified prescriptions of AIT for house dust mites (HDM), grasses (GR) and early flowering trees (EFT) from 2008 to 2017. We compared AIT groups to control groups, which were selected from patients not treated with AIT but with at least 2 prescriptions of symptomatic allergic rhinitis (AR) medication. We measured the impact of AIT treatment on AD using symptomatic AD medication.</div></div><div><h3>Results</h3><div>The use of all 3 forms of AIT resulted in a significant decrease in the necessity for AD medication when compared to the control group. Moreover, in patients who did not present with AD at the outset of the study, AIT was observed to significantly reduce the likelihood of developing AD at a later stage, in comparison to allergic patients who were not subjected to AIT.</div></div><div><h3>Conclusion</h3><div>Our results confirm the positive effects of AIT in patients with AD. The findings of this study illustrate the value of RWE studies as a means of further analysis of AIT as a disease modifier, thus providing a complementary perspective to that gained from clinical studies and enhancing the efficacy of AIT in the future.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101090"},"PeriodicalIF":4.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144771515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement","authors":"Antonino Romano ,&nbsp;Rocco L. Valluzzi ,&nbsp;Emilio Alvarez-Cuesta ,&nbsp;Ignacio Ansotegui ,&nbsp;Riccardo Asero ,&nbsp;Annick Barbaud ,&nbsp;Joan Bartra ,&nbsp;Sevim Bavbek ,&nbsp;Katherine N. Cahill ,&nbsp;Pascal Demoly ,&nbsp;Inmaculada Doña ,&nbsp;María A. Guzmán Meléndez ,&nbsp;Mona Kidon ,&nbsp;Lily Li ,&nbsp;Ricardo Madrigal-Burgaleta ,&nbsp;Joanna S. Makowska ,&nbsp;Hae-Sim Park ,&nbsp;César Picado ,&nbsp;Marek Sanak ,&nbsp;Masami Taniguchi ,&nbsp;Masao Yamaguchi","doi":"10.1016/j.waojou.2025.101086","DOIUrl":"10.1016/j.waojou.2025.101086","url":null,"abstract":"<div><div>Hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) have been classified as immediate (or acute) and delayed. Immediate reactions can be further classified into 4 clinical types: NSAID-exacerbated respiratory disease (N-ERD), NSAID-exacerbated cutaneous disease (NECD), NSAID-induced urticaria/angioedema (NIUA), and single NSAID-induced urticaria/angioedema/anaphylaxis (SNIUAA). Specifically, the NIUA type references reactions to ≥2 NSAIDs belonging to different chemical groups, involving urticaria and/or angioedema in patients with no underlying chronic spontaneous urticaria. However, there are patients meeting cross-reactive criteria for NIUA phenotype who report reactions that involve 2 organ systems (eg, cutaneous and respiratory; cutaneous and gastrointestinal) and have been termed “blended”. In pediatrics, this type of reaction is recognized and has been termed NSAID-induced urticaria/angioedema/anaphylaxis (NIUAA), an acronym we suggest be extended now to adults. There are small subgroups of N-ERD patients who also report skin symptoms and, alternatively, NECD patients who report respiratory symptoms. These 2 subgroups could be diagnosed as having mixed N-ERD and mixed NECD, respectively. In fact, they are patients suffering from N-ERD or NECD who have had reactions consistent with anaphylaxis.</div><div>In the current classifications of NSAID hypersensitivity, the reactions in which NSAIDs act as aggravating factors or cofactors in subjects with sensitization to foods are not included. Recently, this type of reactions has been defined as NSAID-exacerbated food allergy (NEFA) and NSAID-induced food allergy (NIFA), respectively.</div><div>This Statement of the World Allergy Organization (WAO) aims to update both the classification of hypersensitivity reactions to NSAIDs and their diagnosis, addressing the novel issues.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101086"},"PeriodicalIF":4.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144827106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating vaccination dosing strategies for SARS-CoV-2 in patients at high-risk for allergic reactions: Insights from vaccination campaign","authors":"Stefania Nicola MD ,&nbsp;Iuliana Badiu MD ,&nbsp;Nicolò Rashidy MD ,&nbsp;Elena Saracco MD ,&nbsp;Erika Montabone MD ,&nbsp;Luca Lo Sardo MD ,&nbsp;Marzia Boem MD ,&nbsp;Valentina Marmora MD ,&nbsp;Federica Corradi MD ,&nbsp;Andrea Ricotti MSc, MPH ,&nbsp;Richard Borrelli MD ,&nbsp;Giovanni Rolla MD ,&nbsp;Simone Negrini MD, PhD ,&nbsp;Luisa Brussino MD","doi":"10.1016/j.waojou.2025.101095","DOIUrl":"10.1016/j.waojou.2025.101095","url":null,"abstract":"<div><h3>Background</h3><div>The COVID-19 pandemic significantly increased the demand for allergy consultations to evaluate the risk of hypersensitivity reactions in patients either before receiving their first dose of an anti-SARS-CoV-2 vaccine (Group 1) or following suspected allergic reactions after vaccination (Group 2).</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of patients referred to the Immunology and Allergy Unit of the Azienda Ospedaliera Ordine Mauriziano in Turin, Italy, between December 2020 and December 2022. Risk assessment was performed according to Italian and European guidelines, and allergy skin tests were administered when necessary. Patient data were cross-referenced with the SIRVA platform (Regional Vaccination Management Information System) to assess vaccine eligibility, administration, and outcomes.</div></div><div><h3>Results</h3><div>A total of 1222 patients were evaluated (mean age: 52 years; female-to-male ratio 4:1). In Group 1 (n = 914), 137 patients (15%) underwent skin testing, of whom 15 (1.6%) tested positive. Vaccination was recommended for 899 patients (98%), though 184 (20%) did not proceed. Among those vaccinated, 679 (74%) received additional doses, with 48% receiving a third and 11% a fourth dose. In Group 2 (n = 308), 104 patients (33%) underwent skin testing, with 9 (8%) testing positive. Vaccination without restrictions was recommended for 299 patients (97%), but 45 patients (15%) did not proceed. Among the remaining, 262 (85%) received a second dose, 183 (59%) a third, and 29 (9%) a fourth dose. Overall, 1198 patients (98%) had no specific contraindications to vaccination. Only 5 patients (0.4%) were completely exempted from vaccination due to confirmed sensitivity to both polyethylene glycol (PEG) and polysorbate 80 (PS80). An alternative vaccine was recommended for 19 patients; 16 of them proceeded with vaccination and tolerated it without adverse effects.</div></div><div><h3>Conclusions</h3><div>Our findings demonstrate that the majority of high-risk allergic patients can safely receive anti-SARS-CoV-2 vaccines following allergological evaluation. The rate of confirmed excipient allergy was very low, and vaccine adherence was comparable to the general population. This is, to our knowledge, the first study to longitudinally assess the number and types of vaccine doses administered to high-risk allergic individuals.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101095"},"PeriodicalIF":4.3,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of immune-associated biomarkers in diagnosing allergic rhinitis","authors":"Qi Cheng PhD ,&nbsp;Jie Fei MS ,&nbsp;Yuanfen Liao MS ,&nbsp;Hang Lin MD ,&nbsp;Yubao Cui PhD","doi":"10.1016/j.waojou.2025.101084","DOIUrl":"10.1016/j.waojou.2025.101084","url":null,"abstract":"<div><h3>Background</h3><div>Allergic rhinitis (AR), as a prevailing disease worldwide, is a common chronic inflammatory disease of the upper airway; however, its prognosis did not meet expectations of the general public. Regarding the importance of treatment for AR, biomarkers with high sensitivity and precision are in urgent need.</div></div><div><h3>Methods</h3><div>To detect the potential mechanisms associated with the AR pathology, the differentially expressed gene data from the clinical dataset GSE19187 and GSE46171 were used for weighted gene co-expression network analysis. Additionally, 5 machine-learning algorithms were integrated to screen for novel diagnostic biomarkers for AR.</div></div><div><h3>Results</h3><div>This analysis identified 133 genes enriched in the black and purple module pathways from weighted gene co-expression network analysis (WGCNA). The 4 key diagnostic genes—CST1, CST2, SERPINB4, and TOX—were identified through machine learning algorithms and validated for their diagnostic potential with high area under the curve (AUC) values in external datasets. Immune infiltration analysis indicated a higher proportion of resting mast cells in AR samples compared to controls, with CST1, CST2, and SERPINB4 showing high expression in these cells. Real-time PCR validation confirmed that CST1, CST2, and SERPINB4 were upregulated in AR samples while TOX was downregulated.</div></div><div><h3>Conclusion</h3><div>Our study identifies critical molecular markers and immune cell alterations associated with AR, providing insights into its pathogenesis and potential diagnostic biomarkers for clinical application. Future research should focus on validating these findings in larger cohorts to facilitate the development of targeted therapies for AR.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101084"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144713769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of hereditary angioedema attacks on health-related quality of life and work productivity","authors":"Maeve O'Connor MD ,&nbsp;Paula J. Busse MD ,&nbsp;Timothy J. Craig DO ,&nbsp;Cristine Radojicic MD ,&nbsp;H. James Wedner MD ,&nbsp;Sherry Danese MBA, BS ,&nbsp;Julie Ulloa BS ,&nbsp;Vibha Desai PhD ,&nbsp;Tomas Andriotti PhD, MPH ,&nbsp;Paul K. Audhya MD, MBA ,&nbsp;Sandra Christiansen MD","doi":"10.1016/j.waojou.2025.101083","DOIUrl":"10.1016/j.waojou.2025.101083","url":null,"abstract":"<div><h3>Background</h3><div>Hereditary angioedema (HAE) negatively impacts health-related quality of life (HRQoL). Few studies have characterized impairments to HRQoL, work productivity, and well-being during and following HAE attacks.</div></div><div><h3>Methods</h3><div>Patients with ≥1 HAE attack in the previous 3 months were recruited by the United States (US) HAE Association (HAEA) to complete an online survey. Respondents were categorized into those who did (Treated Cohort) and did not (Untreated Cohort) manage their last attack with on-demand treatment (OD). Adapted versions of the EuroQol–Five Dimensions–Five Levels (EQ-5D-5L), EuroQol Visual Analogue Scale (EQ VAS), and Work Productivity and Activity Impairment–General Health assessments were used.</div></div><div><h3>Results</h3><div>Attacks negatively impacted HRQoL and social and physical aspects of well-being in the Treated (N = 94) and Untreated (N = 20) Cohorts. In the Treated Cohort, mean EQ-5D-5L index score was 0.849 “Today” and 0.568 “During the last treated attack,” with the latter score indicating substantial impairment in HRQoL. Mean EQ-5D-5L index scores trended lower as time to OD increased, with mean scores of 0.667 for those treating &lt;1 h and 0.593-0.504 for those treating ≥1 to &lt;8 h from attack onset. The percentage of patients with mild attacks decreased as time to OD increased (from 50% for those treating &lt;1 h to 17–33% for those treating ≥1 h from attack onset), and mean EQ-5D-5L index scores decreased as attack severity increased (mild, 0.742; severe, 0.444). Generally, mean EQ VAS scores decreased as time to OD increased, from 60.1 in those treating &lt;1 h to 53.3 in those treating ≥8 h from attack onset. In the week following attack onset, average levels of absenteeism, presenteeism, and overall work impairment were 15%, 35%, and 39%, respectively. Despite attacks being of milder severity, declines in HRQoL (mean EQ-5D-5L and EQ VAS scores “During the last attack”: 0.661 and 73.0, respectively) and impairments in work productivity (mean level of absenteeism, presenteeism, and overall work impairment: 12%, 32%, and 36%, respectively) were also observed in the Untreated Cohort.</div></div><div><h3>Conclusions</h3><div>Late-treated and untreated attacks were associated with reduced HRQoL and work productivity, driven by attack severity. The negative impact of attacks may be reduced by increasing compliance with HAE guidelines (ie, consider OD for all attacks and treat as soon as possible), and by addressing barriers to OD in general and early treatment in particular.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101083"},"PeriodicalIF":3.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effect of micheliolide against inflammation and oxidative stress in asthma through the MAPK/NF-κB signalling pathway","authors":"Jia Wang ,&nbsp;Dan Han ,&nbsp;Lina Han ,&nbsp;Qinzhen Zhang ,&nbsp;Shaozhuang Liu ,&nbsp;Jiapeng Hu ,&nbsp;Yunxiao Shang","doi":"10.1016/j.waojou.2025.101091","DOIUrl":"10.1016/j.waojou.2025.101091","url":null,"abstract":"<div><h3>Background</h3><div>Asthma involves oxidative stress imbalance and activation of the NLRP3 inflammasome. Micheliolide (MCL), a sesquiterpene lactone compound, has promising anti-inflammatory properties. However, its therapeutic potential in asthma remains unexplored.</div></div><div><h3>Objective</h3><div>We aimed to investigate the therapeutic potential of MCL in asthma by elucidating the molecular mechanisms.</div></div><div><h3>Methods</h3><div>MCL was administered to both an ovalbumin-induced asthmatic mouse model and an interleukin-4/tumour necrosis factor alpha-activated BEAS-2B cell line to evaluate its effects comprehensively on airway inflammation, oxidative stress, and NLRP3 inflammasome activation. Network pharmacology analysis was utilised to evaluate the intricate interactions between asthma and MCL. Additionally, we analyzed the expression levels of critical factors involved in the MAPK/NF-κB signalling pathway.</div></div><div><h3>Results</h3><div>The results demonstrated that MCL effectively mitigated airway hyperresponsiveness in asthma, suppressed inflammation, alleviated oxidative stress, and inhibited NLRP3 inflammasome activation. Furthermore, MCL exhibited notable inhibitory effects on MAPK/NF-κB signalling. Importantly, the inhibitory impact of MCL on asthmatic inflammatory responses was partially reversed by an NF-κB agonist, substantiating that MCL exerts its effects on asthma through the MAPK/NF-κB signalling pathway. These findings highlight MCL as a potent therapeutic candidate for asthma and shed light on the underlying molecular mechanisms driving its therapeutic efficacy.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 8","pages":"Article 101091"},"PeriodicalIF":3.9,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}